2.2. Inclusion criteria
This protocol is extracted from research article:
The therapeutic effects of naringenin on bronchial pneumonia in children
Pharmacol Res Perspect, Jul 26, 2021; DOI: 10.1002/prp2.825

Children were eligible to enter the clinical trial if they met the following six conditions: (a) age from 1.5 to 6 years; (b) the clinical symptoms were in accordance with the diagnostic criteria of bronchial pneumonia in children; (c) with normal gastrointestinal function; (d) free from antibiotic in the past 3 months; (e) had no allergic history of naringenin; and (f) both patients and their statutory guardians provided informed consent and voluntarily joined the study.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.